Gasilus Pharmaceuticals
Revolutionizing Vaccines with Next-Generation Technology
Gasilus Pharmaceuticals is a pioneering vaccine company dedicated to developing innovative solutions for global health challenges. Our breakthrough lies in Chimeric Gas Vesicles (CGVs), a revolutionary protein nanotechnology platform has great potential to transform vaccine development with the following advantages.
CGVs: Designed for Impact
Targeted Delivery: CGVs can deliver precisely chosen protein fragments (epitopes) up to 62 amino acids long, directly stimulating the immune system.
Multifaceted Potential: This targeted approach opens doors for vaccines against a wide range of diseases, including:
Infectious diseases like COVID-19, influenza, and others.
Cancers and autoimmune disorders.
Neurodegenerative diseases like Alzheimer's.
Broader Reach: We are committed to developing vaccines for both human and animal health.
Leading the Way in Vaccine Innovation
Founded in 2020, Gasilus Pharmaceuticals is at the forefront of CGV technology. We are actively driving the development of next-generation vaccines with the potential to improve global health outcomes.